Derrick Rossi, PhD

President and CEO at Convelo Therapeutics

NYSCF Board Member
2010 NYSCF – Robertson Stem Cell Investigator Alumnus
President and CEO, Convelo Therapeutics
Founder, Moderna Therapeutics
Co-Founder, Magenta Therapeutics
Co-Founder, Intellia Therapeutics
Former Associate Professor, Harvard University and Boston Children’s Hospital
PhD, University of Helsinki, Finland
Postdoctoral Training, Stanford University

Bio

Dr. Rossi is a serial biotech entrepreneur and leading stem cell scientist. His efforts in the development of cutting-edge technologies and new therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Time magazine named Dr. Rossi as one of the 100 Most Influential People in the world (Time 100) in 2011. Dr. Rossi earned his BSc and MSc from University of Toronto, and his PhD from the University of Helsinki. He was a Professor at Harvard Medical School and Harvard University and an investigator at Boston Children’s Hospital where he led an academic team working on stem cell biology and regenerative medicine. Discoveries made in Dr. Rossi’s lab have led to the formation of several leading biotechnology companies. His development of modified-mRNA reprogramming was named by Time magazine as one of the top ten medical breakthroughs of 2010. That same year, Dr. Rossi leveraged that technology to found Moderna Therapeutics, a clinical-stage company focused on modified-mRNA therapeutics that is now a leader in the COVID-19 vaccine race. In 2015, Dr. Rossi co-founded Intellia Therapeutics, a publicly traded Cambridge-based company focused on developing CRISPR/Cas9-based therapeutics. In 2016, he co-founded Magenta Therapeutics, which is focused on transforming transplantation medicine. In 2017, he helped launch Convelo Therapeutics, which is developing remyelination therapeutics for patients suffering from demyelination diseases such as multiple sclerosis. He currently serves as the founding CEO of Convelo.

External Links